Characterization of Critically Ill COVID-19 Patients at a Brooklyn Safety-Net Hospital
Authors:
- Stephen CaponeSCStephen Capone
- Shogik AbramyanSAShogik Abramyan
- Brent RossBRBrent Ross
- Joshua RosenbergJRJoshua Rosenberg
- John ZeibeqJZJohn Zeibeq
- Viswanath VasudevanVVViswanath Vasudevan
- Reza SamadRSReza Samad
- Louis GerolemouLGLouis Gerolemou
- Evgeny PinelisEPEvgeny Pinelis
- James GasperinoJGJames Gasperino
- Jose OrsiniJOJose Orsini
Open Access
- 17 August 2020
- journal article
- research article
- Published by Springer Nature in Cureus
- Vol. 12 (8) , e9809
Abstract
The novel coronavirus disease 2019 (COVID-19) pandemic continues to spread across the country with over 3 million cases and 150,000 deaths in the United States as of July 2020. Outcomes have been poor, with reported admission rates to the intensive care team of 5% in China and mortality among critically ill patients of 50% in Seattle. Here we explore the disease characteristics in a Brooklyn safety-net hospital affected by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. A retrospective chart review of COVID-19 positive patients at The Brooklyn Hospital Center who were treated by the intensive care team prior to April 20, 2020. Data was extracted from the electronic health record, analyzed and correlated for outcome. Impact of various clinical treatments was assessed, showing no change in median overall survival (OS) of both hydroxychloroquine with azithromycin or vitamin C with zinc. Supplemental therapies were used in selected patients, and some were shown to increase median OS and patients requiring vasopressor support or invasive mechanical ventilation showed decreased OS. There was no statistically significant difference in overall survival based on ethnicity, healthcare status, or individual medical comorbidities, although a negative trend exists for diabetes. Despite this, there is a trend towards increasingly poor prognosis based on the number of comorbidities and Class 3 obesity. Despite the fact that we show no significant differences in mortality based on ethnicity, insurance status, or individual medical comorbidities, we show a high overall mortality. There is also a trend towards increased overall mortality in Class 3 obesity, which should be further investigated. We suggest that these findings may be attributed to both socioeconomic factors and an increased incidence of total medical comorbidities in our patient population.Keywords
This publication has 19 references indexed in Scilit:
- RETRACTED: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trialInternational Journal of Antimicrobial Agents, 2020
- Covid-19 in Critically Ill Patients in the Seattle Region — Case SeriesNew England Journal of Medicine, 2020
- COVID-19 Does Not Lead to a “Typical” Acute Respiratory Distress SyndromeAmerican Journal of Respiratory and Critical Care Medicine, 2020
- Lung Recruitability in COVID-19–associated Acute Respiratory Distress Syndrome: A Single-Center Observational StudyAmerican Journal of Respiratory and Critical Care Medicine, 2020
- Clinical Characteristics of Coronavirus Disease 2019 in ChinaNew England Journal of Medicine, 2020
- Critical Care Utilization for the COVID-19 Outbreak in Lombardy, ItalyJAMA, 2020
- Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19New England Journal of Medicine, 2020
- Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in ChinaJAMA, 2020
- Double Environmental Injustice — Climate Change, Hurricane Dorian, and the BahamasNew England Journal of Medicine, 2020
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987